Key clinical point: Gene variants associated with inborn errors of immunity were highly prevalent among patients with rheumatic diseases who developed persistent secondary hypogammaglobulinemia after starting on immunomodulatory therapy.
Major finding: Among 64 patients with persistent secondary hypogammaglobulinemia, 48% had such variants.
Study details: Single-center cohort study of patients with autoimmune rheumatic diseases.
Disclosures: Study funders included the German Research Foundation, the German multiorgan Autoimmunity Network, Hannover Medical School, the Rose-marie-Germscheid Foundation, the German Academic Exchange Service, HBRS, the Center for Infection Biology, and the German Center for Infection Research. The investigators reported having no competing interests.
Sogkas G et al. Ann Rheum Dis. 2020 Oct 12. doi: 10.1136/annrheumdis-2020-218280.